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Abstract 
The most common tumors derived from the mesenchyme of the gastrointestinal system 
are stromal tumors. These tumors are typically seen in the stomach and small intestine 
and less frequently in the colon, rectum and esophagus and are very rarely located 
outside the gastrointestinal system. Cure is provided with complete surgical resection 
with resection borders free of tumor. Tumor size, mitotic index, localization, CD117 and 
CD34 negativity in immunohistochemical studies, mucosal ulceration and presence of 
necrosis help to predict recurrence of the illness and patient survival. In high-risk 
gastrointestinal stromal tumors (GISTs) there is an increased rate of recurrence and 
shortened survival despite complete surgical resection. Thus patients with a high-risk 
GIST should be given adjuvant therapy with imatinib mesylate. Sunitinib maleate is 
another FDA-approved agent only for cases who cannot tolerate imatinib or who are 
resistant to it. Herein we present three cases with GISTs in different locations of the 
gastrointestinal system with a review of the relevant literature.  
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Introduction 
Gastrointestinal stromal tumors (GISTs), a different histopathological group of 
intestinal tumors derived from mesenchyme, are seen rarely. Most of them used to be 
classified wrongly as leiomyoma, leiomyosarcoma or leiomyoblastoma on the false belief 
that their origin was smooth muscle [1–3]. Following the improvements in electron 
microscopy and immunohistochemical methods, it was shown that they originated from 
the intestinal pacemaker cells (Cajal cells). These cells, having both muscle and nerve cell 
properties, are located in the submucosa, muscularis mucosa and myenteric plexus in the 
gastrointestinal system [4, 5]. Recently, more information was gained about the cell 
characteristics of these tumors by recognition and discovery of the CD117 antigen, c-kit 
protooncogene production, platelet-derived growth factor a (PDGFRA) and CD34 [6–8]. 
Although GISTs can be seen in any part of the gastrointestinal system, it has been 
reported that more than 50% of cases are located in the stomach [2, 3, 7–9]. The 
commonest symptoms of gastric GISTs are hemorrhage and pain [7, 10]. Most colon 
GISTs are asymptomatic and detected incidentally [11]. It is difficult to predict their 
metastatic potential because malignity does not have any obvious clinical and pathological 
findings [8]. A scheme was published how to predict the clinical behavior of GISTs, based 
on tumor size and number of mitoses in the consensus report of the U.S. National 
Institutes of Health in 2001 [5]. 
Case Reports 
Case 1 was a 28-year-old male patient with complaint of abdominal pain. An abdominal mass was 
detected during physical examination. Upper gastrointestinal system endoscopy and biochemical 
studies did not reveal any abnormalities. Computed tomography (CT) and magnetic resonance imaging 
(MRI) were carried out (fig. 1, fig. 2). Pathological examination of fine needle aspiration biopsy was 
consistent with a malignant mesenchymal tumor. Whipple operation was performed as there was 
pancreatic invasion. The patient was discharged on the 12th postoperative day without any 
complications. 
Case 2 was a 62-year-old male patient with complaint of abdominal pain. Upper gastrointestinal 
system endoscopy revealed external pressure on the fundus of the stomach. A soft tissue mass 
protruding to the fundus of the stomach was found in MRI (fig. 3). Proximal gastrectomy was 
performed and the patient was discharged on the 9th postoperative day without any complications. 
Case 3 was a 38-year-old male patient with rectal bleeding, abdominal pain and anemia. Endoscopy 
revealed no pathology in the upper and lower gastrointestinal system. Tc-99 scintigraphy revealed active 
bleeding in the upper left quadrant (fig. 4). A polypoid lesion was detected in capsule endoscopy in the 
proximal jejunum (fig. 5). Double balloon enterescopy showed a bleeding polypoid mass with a 
diameter of 2 cm which was located at the proximal 50 cm of the jejunal lumen (fig. 6). Segmental 
jejunal resection was carried out and he was discharged on the 6th day after the operation. 
The general properties of the patients are summarized in table 1. Pathologic and 
immunohistochemical properties are summarized in table 2. C-kit was strongly positive in all patients 
(fig. 7). 
Discussion 
GISTs are rare submucosal lesions but are presently detected in increasing frequency 
following the increased use of upper gastrointestinal system endoscopy [7]. The most 
common gastrointestinal system location of GISTs is the stomach (52–60%) [12]. Most 
GIST patients are detected in their 6th or 7th decades, while only 10% are below 40 years 
of age [8]. In some studies, secondary malignancies (pre-diagnosis, con-diagnosis,  
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post-diagnosis) are reported to be as high as 20–30% [9, 13], and in one study it was only 
5% [2]. 
Most patients are diagnosed incidentally as they have nonspecific symptoms or are 
asymptomatic [7]. In one study, it is stated that asymptomatic GISTs can be detected 
more frequently during routine endoscopic examination of the stomach, colon and 
rectum [9]. In another, as examination and endoscopic viewing of the small intestine is 
rather difficult, surgical operations done for irrelevant causes revealed GISTs mostly in 
the small intestine [13]. Incidental GISTs are claimed to have a low or very low risk of 
malignancy [9]. In our third case, the patient had a low-risk small intestine GIST. It was 
diagnosed by Tc-99 scintigraphy, capsule endoscopy and double balloon enteroscopy to 
determine the focus of bleeding preoperatively. This minimized the probability of 
unnecessary surgical interventions.  
Abdominal pain (though not a rule) is the most common symptom [7]. In a study, all 
colonic GIST cases were symptomatic versus only 50% of rectal GIST cases [11]. In our 
cases, the most common symptom was abdominal pain. In the relevant literature, anemia 
and gastrointestinal bleeding are seen in 48% of cases in ulcerated lesions [7]. As the 
GISTs located in the stomach and duodenum were not ulcerated, there was neither 
bleeding nor anemia in our cases. 
In some CT screening studies, big GISTs were found to have a tendency to grow 
lobulated and ectophytic, whereas the small ones had a tendency to grow into the lumen. 
In many studies, a radiological (CT) tumor size >5 cm is found to be correlated with a 
malignancy potential [14, 15]. The malignancy potential can be predicted by anatomical 
location, tumor size and mitosis rate [15]. Especially small intestinal GISTs have more 
malignancy potential than colonic and gastric ones [15, 16]. 
Endoscopic ultrasonography (EUS) is an important diagnostic tool [17]. Although 
endoscopic biopsies are not very useful in diagnosis, needle biopsies performed with EUS 
can be used to identify the cell structure and to study specific markers [3]. Additionally, 
some properties in EUS (tumor size, irregular borders) suggest malignancy [18]. In our 
cases we did not have a chance to use EUS. 
Although in several studies especially the high-risk categories (high, medium, low, very 
low) are reported to be in similar percentages in all three anatomical locations [2, 9], in a 
population-based study, 25% of patients were in the high-risk group [19]. The effect of the 
anatomical location on prognosis is debatable. In one study, anatomical location was 
found to be a prognostic factor independent from age, mitotic index and tumor size [16]. 
In another, the anatomic placement of the GIST was found to have an effect on the 
expression of CD34 and smooth muscle actin [20]. Recently a mutation in exon 9 of c-kit 
was found in small intestinal GISTs and this was related to an increase in tumor 
aggressivity [21]. However, in most studies it is reported that tumor size and mitotic 
index were the most important prognostic factors, that recurrence and death were more 
common in the patients in the high-risk group, and that these patients needed additional 
treatment [5, 8, 11]. 
C-kit tyrosine kinase (CD117) positivity has recently been demonstrated to be at a level 
of 91–99% in GISTs, which paved way to the discovery of their cell origin and better 
diagnostic markers [1, 8]. Although c-kit positivity is thought to be a criterion as a 
diagnostic factor for GIST (fig. 7), convincing reports also exist for kit-negative GISTs. 
These tumors are stated to have a similar tyrosine kinase receptor PDGFRA fraction 
mutation as kit [1, 11]. While CD117 and CD34 are positive in recurrent and metastatic  
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tumors, S-100 and desmin are found to be negative [7]. Other important histological 
properties are necrosis and ulceration [3, 11]. Especially coagulation necrosis is thought 
to be related to malignant behavior [8]. In some studies, the existence of ulceration was 
found to be a statistically significant risk factor for recurrence [7, 8]. In all our cases c-kit 
and CD34 were found to be intensely positive. In the case with small intestine location, 
specific mitochondrial antibody was 100% positive. To determine the risk categories of 
patients, the criteria (table 3) specified by the US National Institutes of Health in 2001 
consensus report were used [5]. Pathologic and immunohistochemical properties of the 
cases were evaluated by means of these criteria (table 2). 
Surgical resection is the preferred treatment modality in localized gastric GISTs 
[1, 3, 9]. Previously a 1–2 cm margin was accepted to be sufficient [10, 22], but it has 
recently been shown that resection of the tumor and a microscopic negative surgical 
border is also sufficient [2]. Addition of lymph dissection to surgical resection is 
unnecessary since GISTs do not metastasize by the lymphatic route [9]. For many 
researchers limited approaches like local excision or wedge resection are suitable for 
gastric GISTs, local excision or segmental resection is suitable for duodenal GISTs, 
segmental resection is suitable for small intestinal or colonic GISTs, and transanal 
excision is suitable for rectal GISTs [2, 9]. Some cases may require wide resection because 
of tumor size and localization [11, 23]. Tumor rupture and spread are related to 
worsening of the illness, tumor recurrences and short survival and these should be 
prevented during surgery [7]. Colorectal GISTs in distant locations are hard to manage 
and this is related to bad prognosis [11]. In our gastric GIST case, enucleation was tried 
first as it was located proximally. However, when no success was achieved, a limited 
resection (proximal gastrectomy) was done. In the duodenal case, a wide resection 
(Whipple operation) was performed because of pancreatic invasion. In the jejunal case, a 
segmental resection was performed as suggested in the literature. Lymph dissection was 
not performed. There were no postoperative complications.  
Although the National Comprehensive Cancer Network recommends laparoscopic 
treatment of tumors <2 cm as an optimal treatment of patients with gastric GISTs [23], 
larger tumors can also be excised safely [10, 24]. In a study comparing laparoscopy and 
open surgery, laparoscopic group of patients were found to have less bleeding and shorter 
hospitalization periods [10]. Recent studies point out that minimally invasive surgery like 
endoscopy could be used in small gastric GISTs [25]. However, since these studies are 
unicentral with a small number of cases, the reliability and efficiency of this treatment is 
unclear. In general, if tumor size is >3 cm and EUS reveals muscularis propria invasion, 
endoscopic enucleation should be avoided [26]. 
With a better understanding of prognostic factors in surgically resected primary 
GISTs, postoperative follow-up strategies and adjuvant treatments have evolved [27]. It 
has been proved that imatinib mesylate is very effective in metastatic GISTs, though its 
effectivity is dependent on the state of mutation [28]. It has been determined that in 
tumors with KIT exon 11 mutation, better results were achieved, while in tumors with 
exon 9 mutation and in tumors without KIT or PDGFRA mutation, the response rate was 
very low. Good results were obtained when sunitinib maleate (multikinase inhibitor) was 
given to patients with metastatic GISTs (with or without KIT exon 9 mutation) who had 
worsening of their illness despite imatinib treatment [27]. Most of the KIT mutations in 
GISTs involve exon 11, whereas other KIT mutations are exon 9, 13 and 17 in decreasing 
order. While GISTs with mutations on exon 11 are most sensitive to imatinib when 
compared to mutations on exon 9 and 13, mutation on exon 17 represents primary 
resistance to imatinib [29]. Although cases with mutations on exon 11 have low-risk  
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disease usually with smaller tumors in addition to good prognosis and usually involve 
older patients especially in gastric locations, exon 9 mutations are associated with 
extragastric locations and bad prognosis with larger tumor size [30]. The most common 
locations for metastasis are the liver, peritoneum, bones and lungs [11]. 
In all GIST cases (benign or malignant), long-term follow-up is essential. There is no 
routine procedure for follow-up. Physical examination should be performed once every 
3–4 months for the first two years, lung X-rays, abdominal CT and blood tests once every 
year, and after operation upper gastrointestinal endoscopy once every 6 months for 
2 years and then once a year. Positron emission tomography, however, should be 
obtained if any anomalies are detected in MRI or CT [7]. Recurrences are most frequently 
seen during the first 2 years and thus follow-up should be done with great care during this 
period [3, 7]. In another study, controls are recommended on a 3–6-month basis for the 
first 3 years, then on a yearly basis for the consecutive 10 years [11]. Our cases were 
followed by the oncology department, and only the patient with duodenal GIST was given 
imatinib treatment as he was in the high-risk group. 
In conlusion, as diagnostic tools and methods have improved, with the help of 
immunohistochemical analyses, GISTs can be diagnosed more easily, thus major surgical 
resections can be prevented and patients can be cured with minimally invasive 
procedures. 
 
 
 
Table 1. Patient demographics and complaints 
 Sex  Age  Location  Symptoms  Risk  category 
Case 1  male  27  duodenum  abdominal pain  high 
Case 2  male  62  stomach  abdominal pain  medium 
Case 3  male  38  jejunum  abdominal pain, rectal bleeding  low 
 
 
Table 2. Pathologic and immunohistochemical data 
 Tumor  diameter 
(cm) 
Number of  
mitoses (50 HPF) 
C-kit (CD117) 
positivity 
CD34  
positivity 
Necrosis/ 
ulceration 
Case1 24  <0  + + +  + + +  + / – 
Case 2  10  <5  + + +  + + +  – / + 
Case 3  2.5  <1  + + +  + + +  – / + 
HPF = High power field. 
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Table 3. Risk determination criteria in GISTs (US NIH 2001 consensus report) 
  Tumor diameter (cm)  Mitosis number (50 HPF) 
Very low risk  <2  <5 
Low risk  ≥2 to ≤5  <5 
Medium risk  <5 
<5–10 
<6–10 
<5 
High risk  >5 
anyone >10 
>5 
anyone >10 
HPF = High power field. 
 
 
 
 
Fig. 1. Abdominal CT of case 1 following oral contrast ingestion. There is a huge mass with a necrotic 
central part at the right side of the abdomen. 
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Fig. 2. Fat suppression. T1 axial MR image of case 1 shows a mass with a hyperintense center 
(mucinous? bleeding?). The border between the pancreas and the mass is unclear and it was interpreted 
as invasion. 
 
 
 
Fig. 3. Fat suppression. T1 axial MR slice of case 2 with contrast enhancement. There is a soft tissue 
mass (arrows) protruding to the fundus of the stomach, with heterogenic contrast. 
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Fig. 4. Increased activity in the upper left quadrant of case 3 at the 2nd hour. The activity has moved 
towards the inferior quadrant at the 4th hour. 
 
 
 
Fig. 5. Polypoid mass in the proximal jejunum in case 3 (capsule endoscopy image). 
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Fig. 6. Polypoid mass in the jejunum seen during double balloon enterescopy in case 3. 
 
 
 
Fig. 7. C-kit was strongly positive in all patients. Hematoxylin and eosin, 40 × 10. 
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